IMR Press / FBL / Volume 14 / Issue 2 / DOI: 10.2741/3267

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Bone marrow transplantation as a strategy for tolerance induction in the clinic
Show Less
1 Divisionof Transplantation, Department of Surgery, Vienna General Hospital, Medical University of Vienna, Austria
2 Department of Otorhinolaryngology, Vienna General Hospital, Medical University of Vienna, Austria
Academic Editor:Frank Dor
Front. Biosci. (Landmark Ed) 2009, 14(2), 611–620; https://doi.org/10.2741/3267
Published: 1 January 2009
(This article belongs to the Special Issue Transplantation: current developments and future directions)
Abstract

The only way to overcome the need for life-long immunosuppression in a transplant recipient is to induce tolerance. Deletional tolerance can be reliably achieved with the induction of mixed chimerism through transplantation of donor bone marrow (BM). Despite the development of increasingly milder BM transplantation (BMT) animal models, BM engraftment in humans still requires considerably toxic conditioning and puts patients at risk for the development of GVHD. However, in a proof-of-concept trial, mixed chimerism and tolerance have been successfully induced in highly selected patients suffering from both end-stage renal disease and multiple myeloma. Meanwhile, there has been notable progress in developing advanced experimental BMT regimens, in particular through the use of costimulation blockers. Costimulation blockade in rodent models allowed the design of BMT protocols entirely devoid of irradiation. Costimulation blockers have also succeeded in more complex protocols in non-human primates. They are under clinical evaluation in renal transplantation as immunosuppressive therapy. Costimulation blockade may lead the way for the development of milder BMT protocols and broader application of mixed chimerism in organ transplantation.

Share
Back to top